• Cy5 amine (non-sulfonated): Labeling Guide

  2026-09-04

  Cy5 amine (non-sulfonated) provides a primary amino handle for covalent fluorescent labeling of compatible proteins, peptides, polymers, and related biomolecular targets. Because it is insoluble in water, it should be dissolved in DMSO or ethanol before transfer into an aqueous labeling workflow and should not be used for direct aqueous, diagnostic, or medical applications.

• FHND004 Targets PBK in Multiple Myeloma

  2026-09-03

  The reference study identifies PDZ-binding kinase (PBK) as a previously underdeveloped target of FHND004 in multiple myeloma and connects this activity to ERK1/2 signaling within the MAPK pathway. Its combination of cell assays, transcriptomics, protein screening, binding validation, and in vivo models provides a preclinical framework for evaluating EGFR-derived compounds beyond canonical EGFR inhibition.

• AZ505: Selective SMYD2 Inhibitor Workflow

  2026-09-02

  A scenario-based guide to using AZ505, a potent and selective SMYD2 inhibitor, in cell viability, proliferation, and cytotoxicity workflows. It explains how SKU B1255 links biochemical potency with practical controls, model selection, data interpretation, and vendor reliability.

• Dual Luciferase Reporter Gene System for Al Stress

  2026-09-02

  Learn how a Dual Luciferase Reporter Gene System can convert the tomato SlSTOP1–SlSLAH1 aluminium-tolerance mechanism into a rigorous promoter-testing strategy. This article emphasizes reporter architecture, normalization limits, and the practical boundaries of applying mammalian-cell reagents to plant regulatory biology.

• Ganetespib (STA-9090) Workflow for Hsp90 Studies

  2026-09-01

  Ganetespib (STA-9090) combines a non-geldanamycin scaffold with potent Hsp90 inhibition, making it useful for connecting client-protein destabilization to cancer-cell phenotypes. This guide translates that mechanism into practical dose-response, target-engagement, release-assay, and troubleshooting workflows while clearly separating oncology evidence from a recent virology insight.

• Z-DEVD-FMK: Caspase-3 Inhibitor Workflows

  2026-09-01

  Z-DEVD-FMK enables controlled dissection of apoptosis, caspase signaling, and calpain-linked proteolysis in cell and neurobiology models. Its use in SADS-CoV research also shows how a caspase-3 inhibitor can connect programmed cell death with antiviral innate-immunity assays.

• Rimonabant (SR141716) for CB1 Mechanism Studies

  2026-08-31

  Rimonabant (SR141716) gives researchers a selective CB1 blockade tool for separating cannabinoid-dependent signaling from appetite, inflammatory, and pain-related phenotypes. Its strongest use is as a mechanistic comparator in carefully controlled cell, feeding, and neuropathic-pain workflows—not as a substitute for pathway-specific validation.

• LGK-974: A Practical PORCN Inhibitor Workflow

  2026-08-31

  A practical guide to using LGK-974 as a PORCN inhibitor for Wnt-dependent cancer models and mechanistic bone research. The workflow connects nanomolar pathway control with target-engagement readouts, dose optimization, and troubleshooting for reproducible experiments.

• Oseltamivir acid for Reliable Cell Assays

  2026-08-30

  Oseltamivir acid (SKU A3689) offers a practical way to standardize neuraminidase-inhibition studies, stock preparation, and viability or cytotoxicity workflows. This scenario-based guide connects product specifications with influenza antiviral research, resistance-aware interpretation, and carefully bounded oncology applications.

• 4-Ethylphenyl Sulfate: Assay Design Guide

  2026-08-29

  Explore how 4-ethylphenyl sulfate connects renal toxin profiling with gut microbiota-brain interaction research. This evidence-based guide translates adsorption findings, chemical specifications, and preclinical neurobehavioral data into practical assay decisions.

• MK-5108: AURKA Evidence in Retinoblastoma

  2026-08-28

  MK-5108 (VX-689) is a highly selective Aurora A inhibitor for testing mitotic dependence in cancer models. This article connects retinoblastoma biology with evidence-driven assay selection, model validation, and xenograft interpretation.

• Substrate Stiffness and LAMB1–FAK–MEK1/2 Dentinogenesis

  2026-08-28

  The reference study shows that substrate stiffness can promote dentinogenesis in odontoblast-like cells through a LAMB1–FAK–MEK1/2 mechanotransduction axis. Its combination of tunable PDMS substrates, mineralization assays, gene-expression analysis, and protein-interaction studies provides a framework for linking material mechanics to reparative dentin formation.

• BI 2536: Reading PLK1 Checkpoint Biology

  2026-08-27

  BI 2536 is a selective PLK1 inhibitor that can reveal how mitotic arrest, checkpoint disassembly, and apoptosis are mechanistically connected. This article translates the p31comet–PLK1 study into a deeper framework for interpreting cancer research assays and tumor models.

• AmpliFold Capture-and-Release for LFA Sensitivity

  2026-08-27

  The ChemRxiv study introduces AmpliFold, a triggered capture-and-release strategy that uses cleavable protein linkers and dual-affinity gold nanoparticles to improve lateral flow assay sensitivity. In a HER2 model, expanding the capture area and tuning receptor density produced up to 16-fold improvement in detection performance, including a 12-fold enhancement with 150 nm nanoparticles in buffer and human serum.

• CCT007093: PPM1D Inhibitor Workflows

  2026-08-26

  CCT007093 is a research-use PPM1D inhibitor for connecting phosphatase activity with early P38 kinase activation, cell viability, and inflammatory cell-death readouts. Its strongest use is an orthogonal workflow that combines biochemical testing, timed phospho-P38 analysis, viability measurements, and pathway-rescue controls.

556 records 6/38 page Previous Next First page 上5页 678910 下5页 Last page